Interview with the Innovators

Supported by BridgeBio

Advanced Practice Providers’ Clinical Practice Guide for ATTR-CM

Utilizing its “Interview with the Innovators” platform, Amyloidosis News has launched a 4-part series of video vignettes with prominent advanced practice transthyretin amyloidosis specialists. The series focuses on the functions of evolutionarily conserved transthyretin, or TTR; destabilization of this protein leading to TTR amyloidosis (ATTR); the optimal approach to address this disease; and objective measures of functional capacity in ATTR-CM.

Utility of Functional Assessments in the Prognosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas TX, explain the usefulness of the six-minute walk test in clinical practice and to patients. Read More ›

Addressing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Through Preservation of Transthyretin
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, review the rationale for stabilization as the optimal approach to addressing transthyretin amyloid cardiomyopathy. Read More ›

The Journey to Diagnosing Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Doesn’t Have to Be a Long One
Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX; Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; and Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL, discuss the debilitating disease burden and the pathway to transthyretin amyloid cardiomyopathy diagnosis. Read More ›

Transthyretin (TTR) Protein in Humans: Stabilization vs Destabilization
In this first video clip, Sarah C. Paciulli, MS, RN, CHFN, NP-C, VCU Health, Richmond, VA; Amy Brownell, MSN, FNP-C, AACC, System Director of Heart Failure, AMITA Health, Chicago, IL; and Lori Roth, MS, PA-C, Advanced Heart Failure Clinic, UT Southwestern Medical Center, Dallas, TX, describe the functions of transthyretin (TTR) in its naturally occurring tetrameric form and resulting damage from TTR destabilization. Read More ›

Amyloidosis News
Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News by subscribing to receive the free AMN e‑Newsletter.